Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, December 31, 2021.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$348.59M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$345.48M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$339.15M
Return on Equity (ROE)
-86.10%
TTM Avg
-112.93%
3Y Avg
-76.30%
5Y Avg
-62.48%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$363.54M
Return on Equity (ROE)
N/A
TTM Avg
34.79%
3Y Avg
145.50%
5Y Avg
100.23%
Market Cap
$366.39M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$330.60M
Return on Equity (ROE)
-41.02%
TTM Avg
-44.84%
3Y Avg
-46.96%
5Y Avg
-38.83%
Market Cap
$329.01M
Return on Equity (ROE)
-226.56%
TTM Avg
-87.78%
3Y Avg
-55.09%
5Y Avg
-55.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $348.85M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -26.14% | -53.80% | -12.25% | 19.21% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -320.77% | -82.83% | -78.63% | -104.90% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -86.10% | -112.93% | -76.30% | -62.48% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Agenus Inc. (AGEN)vs › | $363.54M | N/A | 34.79% | 145.50% | 100.23% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -62.56% | -108.31% | -79.06% | -57.33% |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -41.02% | -44.84% | -46.96% | -38.83% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -226.56% | -87.78% | -55.09% | -55.09% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -7.66% | -10.18% | 260.20% | 144.75% |
ROE
N/A
ROA
6.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2021-12-31 | 74.21% |
| 2021-09-30 | 69.87% |
